ATX inhibitors

Oncology

Tackling the fibroblast cells that form scar tissue around tumours takes down a barrier that prevents or inhibits the effect of many therapies.

News

Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.